Oxstem, an Oxford biotech spin-off focusing on regenerative medicine for age-related diseases, recently raised a record £16.9 million at start-up (Ward, 2016). The money was invested by the local Oxford Sciences Innovation fund and two American venture capital (VC) investors. Why is this important?

Seed and early-stage venture capital were mainly provided by local investors in the past, as entrepreneurial […]